Elastomeric osteoconductive synthetic scaffolds with acquired osteoinductivity expedite the repair of critical femoral defects in rats.
Regenerative medicine aspires to reduce reliance on or overcome limitations associated with donor tissue-mediated repair. Structural bone allografts are commonly used in orthopedic surgery, with a high percentage of graft failure due to poor tissue integration. This problem is aggravated among elderly, those suffering from metabolic conditions, or those undergoing cancer therapies that compromise graft healing. Toward this end, we developed a synthetic graft named FlexBone, in which nanocrystalline hydroxyapatite (50 wt%) was structurally integrated with crosslinked poly(hydroxyethyl methacrylate) hydrogel, which provides dimensional stability and elasticity. It recapitulates the essential role of nanocrystalline hydroxyapatite in defining the osteoconductivity and biochemical microenvironment of bone because of its affinity for biomolecules. Here, we demonstrate that FlexBone effectively absorbed endogenously secreted signaling molecules associated with the inflammation/graft healing cascade upon being press-fit into a 5-mm rat femoral segmental defect. Further, when preabsorbed with a single dose of 400 ng recombinant human (rh) bone morphogenetic protein-2/7 heterodimer, it enabled the functional repair of the critical-sized defect by 8-12 weeks. FlexBone was stably encapsulated by the bridging bony callus and the FlexBone-callus interface was continuously remodeled. In summary, FlexBone combines the dimensional stability and osteoconductivity of structural bone allografts with desirable surgical compressibility and acquired osteoinductivity in an easy-to-fabricate and scalable synthetic biomaterial.
Filion
Tera M
TM
Department of Orthopaedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Li
Xinning
X
Mason-Savas
April
A
Kreider
Jaclynn M
JM
Goldstein
Steven A
SA
Ayers
David C
DC
Song
Jie
J
D000818:Animals; D001672:Biocompatible Materials / Q000138:chemical synthesis / Q000627:therapeutic use*; D018786:Bone Substitutes / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000295:instrumentation*; D019245:Compressive Strength; D005264:Femoral Fractures / Q000473:pathology / Q000601:surgery*; D010012:Osteogenesis; D011474:Prosthesis Design; D051381:Rats; D054457:Tissue Scaffolds; D016896:Treatment Outcome
D001672:Biocompatible Materials; D018786:Bone Substitutes
Tissue Eng Part A. 2008 Aug;14(8):1305-19
18491953
J Biomech. 2007;40(14):3178-86
17524409
Bone. 1998 Jun;22(6):605-12
9626398
J Histochem Cytochem. 2002 Mar;50(3):333-40
11850436
Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S7-21
9917622
Tissue Eng Part A. 2010 Mar;16(3):879-87
19814588
Bone. 2007 Apr;40(4):931-8
17236835
Int Orthop. 2007 Dec;31(6):735-41
17962946
ANZ J Surg. 2007 Aug;77(8):626-31
17635273
J Orthop Res. 2009 Oct;27(10):1306-11
19350632
Orthopedics. 1994 Sep;17(9):809-10, 821
7800607
Bone. 2006 Apr;38(4):547-54
16326155
Bone. 2003 Apr;32(4):387-96
12689682
J Orthop Res. 1989;7(4):585-9
2786956
Bone. 2007 Aug;41(2):247-55
17553763
Nat Genet. 2006 Dec;38(12):1424-9
17099713
Growth Factors. 1996;13(3-4):291-300
8919035
Clin Orthop Relat Res. 2009 Dec;467(12):3249-56
18663547
J Biomed Mater Res A. 2009 Jun 15;89(4):1098-107
18546185
Nat Mater. 2009 Jun;8(6):457-70
19458646
J Biol Chem. 2000 May 26;275(21):16213-8
10748043
J Pharm Sci. 2009 Apr;98(4):1317-75
18729202
Nat Med. 2005 Mar;11(3):291-7
15711561
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5753-8
8650165
J Bone Joint Surg Am. 1999 Jul;81(7):905-17
10428121
Arthritis Rheum. 2009 Mar;60(3):813-23
19248097
J Bone Miner Res. 1997 Aug;12(8):1210-22
9258751
Semin Cell Dev Biol. 2008 Oct;19(5):459-66
18692584
Bone. 2002 Feb;30(2):386-92
11856646
Injury. 2008 Sep;39 Suppl 2:S33-6
18804571